Dr. Mimoun Ayoub, Ph.D., Senior VP, Global Head of Sales & Key Account Management, discusses our broad CDMO capabilities to supply complex modalities such as small to large-scale peptides (including GLP-1s), lipids and oligos, as well as Lipid NanoParticle (LNP) formulation, sterile injectable drug products, and our extensive capacity of small molecule APIs & Drug Products, both highly potent and regular potency for Oral Solid Dosage.
Learn more about our six technology platforms and how we support you in delivering complex modalities to your patients: https://lnkd.in/ejrr4frU#cordenpharma#cdmo#pharma#pharmaceuticals#drugdiscovery#drugdevelopment#pharmaceuticals#lipids#peptides#highlypotent#injectables#lnps
Mamoon, thank you so much for joining us here today. Can you just take a moment to introduce yourself to our audience? Yeah, So Mimi Nayeb, I'm Senior VP and Head of Global Sales and Key Account Management at Gordon Farmer, and I'm based in Basel, Switzer. Corner Farmer has been known to work in the peptide space. Can you talk a little bit about your personal work in that area? Yeah, so I mean we have our site in Colorado and other sites in Europe. We have a couple of decades in experience in peptide manufacturing, development and manufacturing and we are expanding substantially. I mean as you know. There is this. High demand in GLP one agonist on the market and this is actually what is driving the peptide market today, the peptide market growth. And Cordon Pharma follows the growth obviously and as you can remember also during the COVID pandemic. And it was a lipid. So yesterday was the lipid, today it's peptide. So Corden Pharma follows, you know, the growth and where the patients need us most. Yeah, so and as you know, maybe just elaborate a little bit on the peptides, the GLP one especially because this is where we are becoming extremely known in the market. We have been expanding really substantially and as you know, these GLP one are long peptide sequences, sequences and very complex. You know, peptides molecules require a lot of processing engineering and in this case process engineering is even more important than process chemistry itself. It's a combination of both expertises that. Makes somehow Corden Pharma unique on this market. We have all of the streamlined supply chain with regard to solvent supply, waste treatment, raw material supply for such large peptide manufacturing. We're talking about metric tons. So we have done it all. But I would like also to stress the point that Cordon Pharma has not expanded only its large scale capacity in the peptide manufacturing, but also we have invested substantially in the small and medium scale both at Colorado and Frankfurt. So it's very important that we don't have the image of just the large scale peptide manufacturer. So we do really everything from in GMP from grams to metric tons, literally metric tons. So how do you manage to account for a peptide capacity? Yeah. So I think look, it is important to mention that the peptides manufacturing requires very specific. Capacity, very specific equipment, this is not competing with our other platforms. I think that's a very important message I would like to give to our customers. So both upstream processing as well as downstream processing with purification isolation, but tight capacity is completely different from the other type of capacities we use for small molecules, highly potent lipids, carbohydrates, etc. So this is really important to to highlight, yes, so there is no competition. Between the capacity in peptides and the other platforms, so we can completely grow both and Corden Pharma has more than ever the bandwidth to grow all of its six technology platforms. Let's talk about some of the other applications working with because we talked about in the peptides of everything, but I'm curious what other things you're working with. Yeah, so obviously it's a clear message from our CEO and our shareholders that we have and we continue to be committed to grow other platforms. You know we are. The company with with six pillars, actually 6 technology platforms. I can mention those again. We talked about the peptide, small molecules, injectables, oligonucleotide lipids and highly potent. So it's very, very important for all of us that Corn Pharma to continue growing those platforms. And through our commitment, we are actually expanding our capacity also in those other platforms. I can mention a few examples expansion, not only. In terms of capacity, but also investing in new technologies and I can mention a few of those, super fluid chromatography is one of them, flow chemistry to support our small molecule platform. Hot melt extrusion at our solid dose manufacturing plant in Plankstadt and then lipid nanoparticle formulation, you know the delivery of large molecules such as M RNA or plasmid DNA is very, very important area to be in. And Cordon Pharma has just completed an investment and as we speak our plant is being qualified in Italy at our injectable site in Italy to manufacture vaccines, M RNA based vaccines. So this is really showing. Somehow our commitment also to continue the growth in other platforms. Give me one big trend that you're seeing in the broader biopharma space. Yeah, that's an interesting question. Maybe you are where we have the TIDES conference coming up next week and this is really a very good opportunity to talk about the, you know, the large molecules such as in RNA as I mentioned the DNA or any type of gene therapy or gene editing based therapy. And you know the advances in drug delivery of large molecules has opened the door to those molecules to be investigated in not only infectious diseases as we have seen during the pandemic, but also for rare diseases, genetic diseases, but also immuno oncology, right. And just about like few weeks ago, we have seen another CAR T cell therapy approved by the FDA. I believe this is like the number six CAR T cell therapy. Globally and this one last one I believe was for CLL, so chronic lymphocytic leukemia. There's another cancer, blood cancer therapy. I think you know we will see a lot of I would say a mix of large molecules or biomolecules addressing the same indication than what we have seen as of today with small molecules, peptides, oligonucleotides and other type of molecules. Thank you so much for joining us. We really appreciate you taking the time to join us. Thank you.
At dsm-firmenich, we believe that powerful collaborations are the key to elevating research and development. This includes the field of cannabinoid-based early drug development.
Together with Oz Medicann Group pharma – OMG pharma – we pioneer the development of a first-to-market #cannabidiol orally disintegrating tablet (ODT) for insomnia management with:
1️⃣ Optimized bioavailability
2️⃣ Higher active drug loading
3️⃣ Improved pharmacokinetic performance
Beyond #insomnia, our joint expertise is also set to address the unmet need for more patient-friendly cannabinoid-based oral solid dosage forms for numerous conditions. Download our case study for the full story: https://bit.ly/3LqNsPc#cannabinoids#APIs#pharmaceuticals#drugdevelopment#dsmfirmenichPharma#webringprogresstolife#togetherelevatinghealth
Meet our expert speaker Dr. Markus Lubda at the New Updates in Drug Formulation & Bioavailability Conference on August 28th in Copenhagen, Denmark.
Markus will share insights on the critical topic of Enhancing Solubility of PROTACs with Polyvinyl Alcohol.
With up to 60% of new molecular entities (NMEs) facing solubility challenges, this topic is increasingly relevant for both oral and parenteral formulations.
More details here: https://lnkd.in/eQbiyK9c#Pharmaceuticals#DrugFormulation#Bioavailability#SolubilityEnhancement
We are delighted to announce that our latest article on cannabinoid research has been featured in the International Pharmaceutical Industry journal. In this piece, we take a deep dive into the cutting-edge solutions advancing cannabinoid-based drug development, with a lens on bioavailability. Why? Because solid oral dosage forms with optimized bioavailability of these highly promising molecules is the preferred administration route for most patients.
Read the full article to learn about the innovative technologies that are being developed to unlock drug efficacy, including expert insights on our very own research in this space: https://lnkd.in/gWU4ewBi#APIs#pharmaceuticals#drugdevelopment#cannabidiol#cannabinoids#dsmfirmenichPharma
Meet our expert speaker Dr. Markus Lubda at the New Updates in Drug Formulation & Bioavailability Conference on August 28th in Copenhagen, Denmark.
Markus will share insights on the critical topic of Enhancing Solubility of PROTACs with Polyvinyl Alcohol.
With up to 60% of new molecular entities (NMEs) facing solubility challenges, this topic is increasingly relevant for both oral and parenteral formulations.
More details here: https://lnkd.in/dHu7MSj7#Pharmaceuticals#DrugFormulation#Bioavailability#SolubilityEnhancement
We are delighted to announce that our latest article on cannabinoid research has been featured in the International Pharmaceutical Industry journal. In this piece, we take a deep dive into the cutting-edge solutions advancing cannabinoid-based drug development, with a lens on bioavailability. Why? Because solid oral dosage forms with optimized bioavailability of these highly promising molecules is the preferred administration route for most patients.
Read the full article to learn about the innovative technologies that are being developed to unlock drug efficacy, including expert insights on our very own research in this space: https://lnkd.in/eWd-kKsC#APIs#pharmaceuticals#drugdevelopment#cannabidiol#cannabinoids#dsmfirmenichPharma
My team spend much of their time delivering equivalence comparisons to support generic pharma submissions. Get some tips on the typical regulatory requirements in this accessible session. #pharma#rheology
Lets meet at the New Updates in Drug Formulation & Bioavailability Conference on August 28th in Copenhagen, Denmark.
I will will share insights on the critical topic of Enhancing Solubility of PROTACs with Polyvinyl Alcohol.
With up to 90% of new molecular entities (NMEs) facing solubility challenges, this topic is increasingly relevant for both oral and parenteral formulations.
More details here: https://lnkd.in/eR9yi8g7#Pharmaceuticals#DrugFormulation#Bioavailability#SolubilityEnhancement
Meet our expert speaker Dr. Markus Lubda at the New Updates in Drug Formulation & Bioavailability Conference on August 28th in Copenhagen, Denmark.
Markus will share insights on the critical topic of Enhancing Solubility of PROTACs with Polyvinyl Alcohol.
With up to 60% of new molecular entities (NMEs) facing solubility challenges, this topic is increasingly relevant for both oral and parenteral formulations.
More details here: https://lnkd.in/eNNxvXhx#Pharmaceuticals#DrugFormulation#Bioavailability#SolubilityEnhancement
Vice President I Head Commercial Development & Strategic Marketing Mammalian I Lonza I CDMO I Board Member I INSEAD
3moGreat interview! Very insightful and lively! Represents Corden Pharma 100%.